-

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Revance Therapeutics, Inc. (RVNC) Investors

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQ: RVNC) securities between November 25, 2019 and October 11, 2021, inclusive (the “Class Period”). Revance investors have until February 8, 2022 to file a lead plaintiff motion.

Investors suffering losses on their Revance investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to howardsmith@howardsmithlaw.com.

On October 12, 2021, Revance stated that it “remains confident” in its BLA despite a Form 483 issued by the FDA following a recent inspection of the Company’s facility. The Form 483, which had been publicized pursuant to a Freedom of Information Act request, indicated that “[t]he current manufacturing process is not the process proposed for licensure.” The Form 483 also stated that Revance’s “Quality Unit lacks the responsibility and authority for the control, review, and approval of outsourced activities which includes defining the responsibilities and communication processes for quality-related activities in a written agreement.”

On this news, Revance’s stock fell $6.85, or 25%, to close at $20.45 per share on October 12, 2021, thereby injuring investors.

Then, on October 15, 2021, Revance disclosed receipt of a Complete Response Letter , which stated that the FDA “is unable to approve the BLA in its present form” due to “deficiencies related to the FDA’s onsite inspection of Revance’s manufacturing facility.”

On this news, Revance’s stock fell $8.90, or 39%, to close at $13.81 per share on October 18, 2021, thereby injuring investors further.

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) quality control deficiencies existed at the Company’s manufacturing facility for DAXI; (2) the foregoing deficiencies decreased the likelihood that the FDA would approve the DAXI BLA in its current form; (3) accordingly, it was unlikely that the DAXI BLA would obtain FDA approval within the timeframe the Company had represented to investors; and (4) as a result, the Company’s public statements were materially false and misleading at all relevant times.

If you purchased Revance securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com

Law Offices of Howard G. Smith

NASDAQ:RVNC

Release Versions

Contacts

Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com

More News From Law Offices of Howard G. Smith

Deadline Alert: Lennar Corporation Stockholders Face January 11, 2027 Lead Plaintiff Deadline in Securities Fraud Class Action, The Law Offices of Howard G. Smith Highlights

BENSALEM, Pa.--(BUSINESS WIRE)--Lennar Corporation ("Lennar" or the "Company") (NYSE: LEN) investors who wish to serve as lead plaintiff in a pending securities fraud class action lawsuit must move the Court by January 11, 2027. The suit was filed on behalf of investors who purchased or otherwise acquired the Company's securities from February 7, 2025 through October 2, 2026, inclusive. The Law Offices of Howard G. Smith today highlighted the deadline in the case, Triggs v. Lennar Corporation et...

Did You Lose Money on Deutsche Bank Aktiengesellschaft Stock? The Law Offices of Howard G. Smith Announces Securities Fraud Investigation After 4.66% Share Price Decline

BENSALEM, Pa.--(BUSINESS WIRE)--Investors who suffered losses on Deutsche Bank Aktiengesellschaft ("Deutsche Bank" or the "Company") stock may have claims to recover those losses. The Law Offices of Howard G. Smith today reported that it is conducting a securities fraud investigation on behalf of Deutsche Bank Aktiengesellschaft (NYSE: DB) investors into whether the Company may have violated the federal securities laws. Investors with losses on Deutsche Bank Aktiengesellschaft securities can co...

Securities Fraud Class Action Lawsuit Pending Against Nuscale Power Corporation: The Law Offices of Howard G. Smith Highlights Lead Plaintiff Deadline

BENSALEM, Pa.--(BUSINESS WIRE)--Nuscale Power Corporation ("Nuscale" or the "Company") (NYSE: SMR) is the subject of a securities fraud class action lawsuit filed on behalf of investors who purchased or otherwise acquired the Company's securities from February 27, 2026 through September 10, 2026, inclusive. The Law Offices of Howard G. Smith today reported the lawsuit, Chiu-Yueh Chang v. NuScale Power Corporation et al., which was filed on November 11, 2026 in the U.S. District Court Oregon Dis...
Back to Newsroom